Elamipretide research
What PubMed holds on Elamipretide, sorted by study design: the papers this site relies on, every clinical-trial publication PubMed tags, and the newest additions.
- PubMed records
- 470
- Trial publications
- 2119 randomized
- Reviews
- 97
- Human-subject tagged
- 201
- Animal-only
- 170
- Clinical-trial publications 21
- Reviews 97
- Animal-only studies 170
- Other (in vitro, chemistry, commentary, unindexed) 182
Studies this site relies on
Ordered by strength of design. Conclusions are quoted verbatim from each abstract as indexed by PubMed; read the full paper before relying on any of them.
-
Efficacy and Safety of Elamipretide in Individuals With Primary Mitochondrial Myopathy: The MMPOWER-3 Randomized Clinical Trial
Karaa A, Bertini E, Carelli V, et al.
Subcutaneous elamipretide treatment did not improve outcomes in the 6MWT and PMMSA TFS in patients with PMM. However, this phase-3 study demonstrated that subcutaneous elamipretide is well-tolerated.
-
A phase 2/3 randomized clinical trial followed by an open-label extension to evaluate the effectiveness of elamipretide in Barth syndrome, a genetic disorder of mitochondrial cardiolipin metabolism
Reid Thompson W, Hornby B, Manuel R, et al.
In this interventional clinical trial in BTHS, daily administration of elamipretide led to improvement in BTHS symptoms.
-
Long-term efficacy and safety of elamipretide in patients with Barth syndrome: 168-week open-label extension results of TAZPOWER
Thompson WR, Manuel R, Abbruscato A, et al.
Elamipretide was associated with sustained long-term tolerability and efficacy, with improvements in functional assessments and cardiac function in BTHS.
-
Novel Mitochondria-Targeting Peptide in Heart Failure Treatment: A Randomized, Placebo-Controlled Trial of Elamipretide
Daubert MA, Yow E, Dunn G, et al.
This is the first study to evaluate elamipretide in heart failure with reduced ejection fraction and demonstrates that a single infusion of elamipretide is safe and well tolerated. High-dose elamipretide resulted in favorable changes in left ventricular volumes that correlated with peak plasma concentrations, supporting a temporal …
-
Elamipretide: First Approval
Shirley M
Elamipretide is also under phase III clinical development for use in the treatment of dry age-related macular degeneration and mitochondrial myopathies. This article summarizes the milestones in the development of elamipretide leading to this first approval for Barth syndrome.
Clinical-trial publications in PubMed
21 records carry PubMed’s clinical-trial publication type. Tagging is done by NLM indexers and occasionally includes secondary analyses.
Newest records
The most recent PubMed additions for this query at the data-edition date, regardless of design.
- Pre-qualifications, learning strategies, and study satisfaction among medical students: insights from a multicenter German study Med Educ Online · 2026 · Primary study
- Seawater immersion reshapes the temporal dynamics of traumatic brain injury and reveals mitochondrial oxidative stress as a modifiable therapeutic target Exp Neurol · 2026 · Primary study
- Mitochondria-targeted MXene-based nanozymes promote mitophagy and inhibit mtDNA-triggered cGAS/STING inflammation in osteoarthritis Bioact Mater · 2026 · Primary study
- Disruption of hippocampal mitochondrial function underlies opioid-induced postoperative cognitive dysfunction in aged rats Brain Behav Immun · 2026 · Primary study
- Mitochondrial Quality Control in Degenerative Musculoskeletal Diseases: Signaling Networks and Therapeutic Landscapes Adv Sci (Weinh) · 2026 · Review
- Elamipretide Rejuvenates Oocyte Quality and Restores Female Fertility During Reproductive Aging Aging Cell · 2026 · Primary study
- Oral Colon- and Mitochondria-Targeted Nanoparticles Alleviate Ulcerative Colitis by Reeducating Macrophage Polarization via SIRT3/FOXO3a-Mediated Mitochondrial Restoration J Gastroenterol Hepatol · 2026 · Primary study
- Mitochondrial Quality Control in Inherited Mitochondrial Cardiomyopathy: Convergent Pathobiology and a Testable Therapeutic Framework Int J Mol Sci · 2026 · Review
- Engineered Mitochondria-Targeted Biomimetic Hybrid Nanovesicles Ameliorate Rheumatoid Arthritis via Regulating Macrophage Autophagy and cGAS-STING Signaling ACS Appl Mater Interfaces · 2026 · Primary study
- The Oxidative-Mitochondrial-Inflammatory Axis in Retinitis Pigmentosa: Extracellular mtDNA as Biomarker and Therapeutic Read-Out Antioxidants (Basel) · 2026 · Review